Viveve (NSDQ:VIVE) said today it inked 6 new distribution deals to expand the availability of its Viveve non-surgical treatment for post-partum laxity of the vaginal introitus to 14 Latin American countries.
The women’s health company said it inked deals with Sirex S.A., Torregal, Alphaeon Columbia S.A.S., Vitre-Tech, Coolmed S.A., Adenor S.A. and MARC Group International to bring the system to Argentina, Peru, Paraguay, Chile, Ecuador, Mexico, Panama, Costa Rica, Guatemala and the Dominican Republic.
“The Latin American region represents one of the world’s largest markets for aesthetic medical procedures. Our collaboration with a distinguished group of distribution partners will help us to increase our presence in the region while providing outstanding service and customer support,” prez & chief biz officer Jim Atkinson said in a press release.
Viveve touted that it now has 23 exclusive distribution deals covering 65 countries around the world, with regulatory clearance in 25 of those countries so far.
“We believe the combination of our internationally patented technology, the experience and professionalism of our partners, and the acceptance of innovative medical procedures in all of our target markets will advance Viveve’s reputation as a leading provider of women’s health products in this important region. Available safety and efficacy data continue to support the use of Viveve Treatment as a painless procedure to treat the common condition of vaginal laxity, which can profoundly impact a woman’s sexual satisfaction and quality of life,” CEO Patricia Scheller said in prepared remarks.
In June, Viveve said its uplisting to the NASDAQ exchange grossed $15.5 million, including an unwriters over-allotment. Sunnyvale, Calif.-based Viveve said it sold more than 3.1 million shares at $5 apiece, for net proceeds of about $14 million.
Earlier in the month Viveve tweaked the value of the flotation, saying it expecting to sell 2.7 million shares for a gross of $13.5 million. The company pulled the trigger on a 1-for-8 reverse split into place in April, and said in May that it planned to offer 1.6 million shares at $8 a piece.